SCM
PSTX

Silverarc Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Silverarc Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,012,307
Closed -$9.72M – 85
2024
Q4 		$9.72M Sell
1,012,307
-2,675,241
-73% -$14M 2.13% 16
2024
Q3 		$10.5M Buy
3,687,548
+79,549
+2% +$246K 2.37% 14
2024
Q2 		$10.5M Buy
3,607,999
+11,523
+0.3% +$31.5K 2.49% 11
2024
Q1 		$11.5M Sell
3,596,476
-109,303
-3% -$364K 3.19% 11
2023
Q4 		$12.5M Buy
3,705,779
+137,794
+4% +$355K 3.71% 5
2023
Q3 		$8.49M Buy
3,567,985
+622,037
+21% +$1.3M 2.57% 10
2023
Q2 		$5.18M Buy
2,945,948
+256,647
+10% +$656K 1.6% 22
2023
Q1 		$8.28M Buy
2,689,301
+459,301
+21% +$2.75M 3.42% 4
2022
Q4 		$11.8M Sell
2,230,000
-324,277
-13% -$1.48M 3.38% 4
2022
Q3 		$9.02M Buy
2,554,277
+2,173,671
+571% +$7.19M 3.05% 9
2022
Q2 		$982K Buy
380,606
+140,910
+59% +$392K 0.3% 54
2022
Q1 		$1.07K Buy
239,696
+4,764
+2% +$21.5K 0.44% 52
2021
Q4 		$1.6M Buy
+234,932
New +$1.6M 0.65% 45

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Silverarc Capital Management's PSTX Position: Q1 2025 in Review

Silverarc Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 1,012,307 shares — an estimated $9.72M sold.

Silverarc Capital Management first reported a position in PSTX in Q4 2021 and held it in 13 quarters. The position peaked at $12.5M in Q4 2023. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Silverarc Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 1,012,307 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $9.72M.
  • Silverarc Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2021 and held it in 13 quarters.
  • Silverarc Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $12.5M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.